ProQR Submits Clinical Trial Application for AX-0810
ProQR Therapeutics NV (Nasdaq: PRQR) has made a significant stride in its clinical journey by submitting a Clinical Trial Application (CTA) to the European Medicines Agency (EMA). This submission is for initiating a Phase 1 study of AX-0810, aimed at targeting NTCP, a key liver cell protein responsible for bile acid transport.
Evaluating Safety and Efficacy
This first-in-human trial of AX-0810 will assess safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers. The anticipated initial data is set to emerge in the upcoming months, signaling a vital development in liver disease treatment. According to ProQR, the Phase 1 study will focus on understanding how AX-0810 interacts within the body, which is particularly relevant considering its potential role in addressing cholestatic liver diseases.
Innovation Through Axiomer™ Technology
AX-0810 leverages ProQR’s unique Axiomer™ technology platform, an advanced RNA editing approach designed to modify gene expression. This investigational drug aims to alleviate toxic bile acid buildup in the liver that can lead to severe complications, including inflammation and fibrosis. The technology exploits the natural ADAR (Adenosine Deaminase Acting on RNA) mechanisms to selectively edit RNA sequences, promising a novel way to address liver-related health issues.
ProQR's Vision for RNA Therapies
“This CTA submission is a monumental milestone for us, propelling our Axiomer RNA editing platform into the clinic,” expressed Cristina Lopez Lopez, MD, PhD, Chief Medical Officer of ProQR. The company aims to fulfill a significant unmet medical need in cholestatic liver diseases, presenting AX-0810 as a therapeutic candidate grounded in robust human genetics and preclinical findings.
Understanding Cholestatic Liver Diseases
Cholestatic liver diseases are characterized by the accumulation of toxic bile acids, which can lead to serious health issues. AX-0810 targets NTCP to modulate bile acid absorption effectively and may offer a breakthrough in treating conditions previously deemed challenging to manage.
Potential Benefits of AX-0810
AX-0810’s design includes GalNac technology to enhance liver targeting, which improves the therapeutic landscape for patients suffering from cholestatic diseases. By selectively modulating NTCP function, AX-0810 presents a promising alternative aimed at mitigating the progression of liver damage commonly seen in affected individuals.
About ProQR Therapeutics
ProQR Therapeutics is committed to revolutionizing the treatment landscape through innovative RNA-based therapies. The company’s Axiomer technology platform holds the potential to treat a wide array of diseases by making precise RNA edits that can reverse mutations or enhance therapeutic outcomes. ProQR continues to grow its pipeline of promising candidates with the mission of developing life-changing treatments for both rare and common diseases.
For more information about ProQR and its groundbreaking work, please visit www.proqr.com.
Frequently Asked Questions
What is AX-0810?
AX-0810 is an investigational RNA editing oligonucleotide aimed at treating cholestatic liver diseases by targeting NTCP to reduce bile acid accumulation.
How does ProQR's Axiomer technology work?
Axiomer technology utilizes the body's natural ADAR mechanisms to make precise adjustments to RNA, potentially leading to innovative treatments for various diseases.
When does the preliminary data for AX-0810 become available?
Initial data from the Phase 1 study of AX-0810 is expected to be available within a few months following the commencement of the trial.
What are cholestatic liver diseases?
Cholestatic liver diseases result from toxic bile acid accumulation, leading to liver inflammation and damage, with few effective treatment options currently available.
How is ProQR supporting patients?
ProQR is dedicated to addressing unmet medical needs by developing transformative RNA therapies designed to improve health outcomes for patients suffering from various diseases.
